|
1
|
Arai T, Oshima M, Uemura M, Matsunaga T, Ashizawa T, Suhara Y, Morii M, Yoneyama H, Usami Y, Harusawa S, Komeda S, Hirota Y. Azolato-Bridged Dinuclear Platinum(II) Complexes Exhibit Androgen Receptor-Mediated Anti-Prostate Cancer Activity. Inorg Chem 2024; 63:20951-20963. [PMID: 39258898 PMCID: PMC11539055 DOI: 10.1021/acs.inorgchem.4c01093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2024] [Revised: 08/06/2024] [Accepted: 08/27/2024] [Indexed: 09/12/2024]
Abstract
Prostate cancer is an androgen-dependent malignancy that presents a marked treatment challenge, particularly after progression to the castration-resistant stage. Traditional treatments such as androgen deprivation therapy often lead to resistance, necessitating novel therapeutic approaches. Previous studies have indicated that some of the azolato-bridged dinuclear platinum(II) complexes (general formula: [{cis-Pt(NH3)2}2(μ-OH)(μ-azolato)]X2, where azolato = pyrazolato, 1,2,3-triazolato, or tetrazolato and X = nitrate or perchlorate) inhibit androgen receptor (AR) signaling. Therefore, here we investigated the potential of 14 such complexes as agents for the treatment of prostate cancer by examining their antiproliferative activity in the human prostate adenocarcinoma cell line LNCaP. Several of the complexes, particularly 5-H-Y ([{cis-Pt(NH3)2}2(μ-OH)(μ-tetrazolato-N2,N3)](ClO4)2), effectively inhibited LNCaP cell growth, even at low concentrations, by direct modulation of AR signaling, and by binding to DNA and inducing apoptosis, which is a common mechanism of action of Pt-based drugs such as cisplatin (cis-diamminedichloridoplatinum(II)). Comparative analysis with cisplatin revealed superior inhibitory effects of these complexes. Further investigation revealed that 5-H-Y suppressed mRNA expression of genes downstream from AR and induced apoptosis, particularly in cells overexpressing AR, highlighting its potential as an AR antagonist. Thus, we provide here insights into the mechanisms underlying the antiproliferative effects of azolato-bridged complexes in prostate cancer.
Collapse
Affiliation(s)
- Tasuku Arai
- Laboratory
of Biochemistry, Department of Bioscience and Engineering, College
of Systems Engineering and Science, Shibaura
Institute of Technology, Saitama, Saitama 337-8570, Japan
- Medicinal
Chemistry and Organic Synthesis, Department of Systems Engineering
and Science, Graduate School of Engineering and Science, Shibaura Institute of Technology, Saitama, Saitama 337-8570, Japan
| | - Masashi Oshima
- Laboratory
of Biochemistry, Department of Bioscience and Engineering, College
of Systems Engineering and Science, Shibaura
Institute of Technology, Saitama, Saitama 337-8570, Japan
- Department
of Urology, Jichi Medical University Saitama
Medical Center, Saitama, Saitama 330-8503, Japan
- Division
of Hematology and Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, United States
| | - Masako Uemura
- Faculty
of Pharmaceutical Sciences, Suzuka University
of Medical Science, Suzuka, Mie 513-8670, Japan
| | - Takeshi Matsunaga
- Laboratory
of Biochemistry, Department of Bioscience and Engineering, College
of Systems Engineering and Science, Shibaura
Institute of Technology, Saitama, Saitama 337-8570, Japan
| | - Taiki Ashizawa
- Laboratory
of Biochemistry, Department of Bioscience and Engineering, College
of Systems Engineering and Science, Shibaura
Institute of Technology, Saitama, Saitama 337-8570, Japan
- Medicinal
Chemistry and Organic Synthesis, Department of Systems Engineering
and Science, Graduate School of Engineering and Science, Shibaura Institute of Technology, Saitama, Saitama 337-8570, Japan
| | - Yoshitomo Suhara
- Medicinal
Chemistry and Organic Synthesis, Department of Systems Engineering
and Science, Graduate School of Engineering and Science, Shibaura Institute of Technology, Saitama, Saitama 337-8570, Japan
- Laboratory
of Organic Synthesis and Medicinal Chemistry, Department of Bioscience
and Engineering, College of Systems Engineering and Science, Shibaura Institute of Technology, Saitama, Saitama 337-8570, Japan
| | - Magotoshi Morii
- Faculty
of Pharmaceutical Sciences, Suzuka University
of Medical Science, Suzuka, Mie 513-8670, Japan
| | - Hiroki Yoneyama
- Department
of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka 569-1094, Japan
| | - Yoshihide Usami
- Department
of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka 569-1094, Japan
| | - Shinya Harusawa
- Department
of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka 569-1094, Japan
| | - Seiji Komeda
- Faculty
of Pharmaceutical Sciences, Suzuka University
of Medical Science, Suzuka, Mie 513-8670, Japan
| | - Yoshihisa Hirota
- Laboratory
of Biochemistry, Department of Bioscience and Engineering, College
of Systems Engineering and Science, Shibaura
Institute of Technology, Saitama, Saitama 337-8570, Japan
- Medicinal
Chemistry and Organic Synthesis, Department of Systems Engineering
and Science, Graduate School of Engineering and Science, Shibaura Institute of Technology, Saitama, Saitama 337-8570, Japan
| |
Collapse
|
|
2
|
Uemura M, Hiramoto K, Yoneyama H, Harusawa S, Komeda S. Introduction of Fluorine into Antitumor-Active Dinuclear Platinum(II) Complexes Leads to Modulation of In Vivo Antitumor Activity in Mice. Inorg Chem 2022; 61:12155-12164. [PMID: 35876345 DOI: 10.1021/acs.inorgchem.2c01126] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Tetrazolato-bridged dinuclear platinum(II) complexes ([{cis-Pt(NH3)2}2(μ-OH)(μ-5-R-tetrazolato-N2,N3)]2+; tetrazolato-bridged complexes) show remarkable cytotoxic effects in vitro and antitumor activity in vivo. Here, we examined the structure-activity relationship of a series of fluorine-containing derivatives (R = CFH2, CF2H, or CF3), focusing on their lipophilicity, cellular accumulation, cytotoxicity, interactions with a nucleobase and double-stranded deoxyribonucleic acid, and in vivo antitumor efficacy. Fluorination had a little effect on the properties of the derivatives in vitro; however, marked differences in in vitro cytotoxicity and in vivo tumor growth inhibition activity were observed. In BALB/c mice bearing colon-26 tumors, the antitumor efficacies of the derivatives were markedly altered, even by changing the number of fluorine atoms by one. In addition, one derivative, [{cis-Pt(NH3)2}2(μ-OH)(μ-5-difluoromethyltetrazolato-N2,N3)](NO3)2, showed a significantly higher antitumor efficacy compared with oxaliplatin, a current first-line drug and the only platinum-based drug approved for the treatment of colon cancer. Together, the present results indicate that introducing fluorine into tetrazolato-bridged complexes may be useful for modulating in vivo activities.
Collapse
Affiliation(s)
- Masako Uemura
- Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Mie 513-8670, Japan
| | - Keiichi Hiramoto
- Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Mie 513-8670, Japan
| | - Hiroki Yoneyama
- Faculty of Pharmaceutical Sciences, Osaka Medical and Pharmaceutical University, Osaka 569-1094, Japan
| | - Shinya Harusawa
- Faculty of Pharmaceutical Sciences, Osaka Medical and Pharmaceutical University, Osaka 569-1094, Japan
| | - Seiji Komeda
- Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Mie 513-8670, Japan
| |
Collapse
|